



Origination: 6/1/2008
Last Approved: 7/26/2017
Last Revised: 7/26/2017
Next Review: 7/25/2020
Owner: Jason Arimura: VCMC - Pharmacy
Policy Area: Administrative - Patient Care
References:

100.087 Anticoagulation Management

POLICY:

This policy provides evidence-based recommendations that help ensure the safe and effective use of oral and parenteral anticoagulants for the prevention and treatment of various thrombotic disorders.

- A. Anticoagulant therapy shall be individualized to each patient.
- B. Clinical judgment shall be employed at the time of initiation, continuation and with the decision to stop anticoagulation.
- C. Anticoagulants that are packaged as oral unit-dose medications, pre-filled syringes, and pre-mixed infusion bags shall be used, when available, to minimize the risk of compounding and labeling errors.
- D. Anticoagulation Committee, Medication Error Reduction Improvement Team (MERIT) and Pharmacy & Therapeutics (P&T) Committee shall evaluate anticoagulation use, identify potential safety issues and modify any protocols and/or clinical practice guidelines addressed in this policy as needed.

PROCEDURE:

- A. Providers shall become familiar with the protocols and clinical practice guidelines addressed in this policy. Providers shall place orders for the desired anticoagulation therapy and relevant baseline labs.
- B. Pharmacists shall review and verify the physician order for appropriate indication, baseline labs, dosage and ensure appropriate monitoring takes place for the duration of anticoagulation therapy.
- C. Nursing staff shall review the seven rights of medication administration prior to administering any anticoagulant therapy. Continuous infusions shall be delivered via smart infusion pump using the appropriate guardrail information. A double check by a second nurse shall be performed and documented in the electronic health record for argatroban infusions, enoxaparin injections, fondaparinux injections and heparin infusions. For argatroban and heparin infusions, the medication and the smart infusion pump settings shall be double-checked at initiation of the infusion, with any rate changes, and when stopping or restarting the infusion.
- D. Nurses, pharmacists and providers share the responsibility to assess for signs and symptoms of bleeding and potential treatment failure (i.e. recurrent thrombosis).
- E. Adverse drug events, medication errors and near-misses of medication errors should be reported via the appropriate notification system.

ANTICOAGULATION MANAGEMENT PROTOCOLS & CLINICAL PRACTICE GUIDELINES

- A. Attachment A: Warfarin Protocol
- B. Attachment B: Heparin Protocol
- C. Attachment C: Low Molecular Weight Heparin Protocol
- D. Attachment D: Argatroban Infusion Protocol
- E. Attachment E: Clinical Practice Guideline: Direct Oral Anticoagulants
- F. Attachment F: Clinical Practice Guideline: Bleeding Associated with Warfarin
- G. Attachment G: Clinical Practice Guideline: Bleeding Associated with Direct Oral Anticoagulants
- H. Attachment H: Clinical Practice Guideline: Anticoagulation Management Around Epidural/Intrathecal/ Lumbar Puncture
- I. Attachment I: Clinical Practice Guideline: Thromboembolism (DVT/PE) Prevention in Hospitalized Patients
- J. Attachment J: Clinical Practice Guideline: Non-ST Elevation Myocardial Infarction (NSTEMI)
- K. Attachment K: Clinical Practice Guideline: ST Elevation Myocardial Infarction (STEMI)
- L. Attachment L: Adult IV Administration Guidelines

All revision dates:

7/26/2017, 10/1/2016, 8/1/2015, 12/1/2010

Attachments:

[Attachment A - Warfarin Protocol.pdf](#)
[Attachment B - Adult Heparin Infusion Protocol.pdf](#)
[Attachment C - Low Molecular Weight Heparin \(Enoxaparin\) Protocol.pdf](#)
[Attachment D - Adult Argatroban Drip Protocol.pdf](#)
[Attachment E - Guidelines for Prescribing Direct Oral Anticoagulants.pdf](#)
[Attachment F - Bleeding Associated with Warfarin.pdf](#)
[Attachment G - Bleeding Associated with Direct Oral Anticoagulants.pdf](#)
[Attachment H - Anticoagulation Management Around Epidural-IT-LP.PDF](#)
[Attachment I - Thromboembolism Prevention in Hospitalized Patients.pdf](#)
[Attachment J - NSTEMI.PDF](#)
[Attachment K - STEMI.PDF](#)
[Attachment L - IV Medication Guidelines for Adults.pdf](#)

Approval Signatures

Approver	Date
Tracy Chapman: VCMC - Med Staff	7/26/2017
Bryan Wong: Physician	6/27/2017
Michelle Sayre: Chief Nursing Officer	6/27/2017
Jason Arimura: VCMC - Pharmacy	6/13/2017

COPY